BioLineRx annual debt-to-equity ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioLineRx Debt-to-Equity Ratio Growth & History (BLRX)
BioLineRx's debt-to-equity ratio was 0.31 for fiscal 2025.
View full BioLineRx company overviewBioLineRx annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.31 | −0.14 | −30.79% |
| 2024 | 2024-12-31 | 0.45 | 0.08 | +20.38% |
| 2023 | 2023-12-31 | 0.38 | 0.30 | +416.01% |
| 2022 | 2022-12-31 | 0.07 | 0.00 | +6.48% |
| 2021 | 2021-12-31 | 0.07 | −0.28 | −80.42% |
| 2020 | 2020-12-31 | 0.35 | 0.04 | +11.36% |
| 2019 | 2019-12-31 | 0.31 | 0.06 | +21.97% |
| 2018 | 2018-12-31 | 0.26 | 0.25 | +5331.82% |
| 2017 | 2017-12-31 | 0.00 | −0.01 | −51.72% |
| 2016 | 2016-12-31 | 0.01 | — | — |
BioLineRx quarterly debt-to-equity ratio
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.58 | 0.28 | +96.69% |
| Q1 2026 | 2026-03-31 | 0.54 | −0.11 | −17.42% |
| Q4 2025 | 2025-12-31 | 0.31 | −0.14 | −30.79% |
| Q3 2025 | 2025-09-30 | 0.58 | — | — |
| Q2 2025 | 2025-06-30 | 0.29 | −0.60 | −67.33% |
| Q1 2025 | 2025-03-31 | 0.66 | — | — |
| Q4 2024 | 2024-12-31 | 0.45 | 0.08 | +20.38% |
| Q2 2024 | 2024-06-30 | 0.90 | 0.66 | +274.71% |
| Q4 2023 | 2023-12-31 | 0.38 | 0.30 | +416.01% |
| Q2 2023 | 2023-06-30 | 0.24 | 0.19 | +418.24% |
| Q4 2022 | 2022-12-31 | 0.07 | 0.00 | +6.48% |
| Q2 2022 | 2022-06-30 | 0.05 | −0.02 | −34.70% |
| Q4 2021 | 2021-12-31 | 0.07 | −0.28 | −80.42% |
| Q2 2021 | 2021-06-30 | 0.07 | −0.09 | −55.96% |
| Q4 2020 | 2020-12-31 | 0.35 | 0.04 | +11.36% |
| Q2 2020 | 2020-06-30 | 0.16 | 0.06 | +61.28% |
| Q4 2019 | 2019-12-31 | 0.31 | 0.06 | +21.97% |
| Q2 2019 | 2019-06-30 | 0.10 | 0.10 | +4848.17% |
| Q4 2018 | 2018-12-31 | 0.26 | 0.25 | +5331.82% |
| Q2 2018 | 2018-06-30 | 0.00 | — | — |
| Q4 2017 | 2017-12-31 | 0.00 | — | — |
BioLineRx debt-to-equity ratio trends
Over the last five fiscal years, BioLineRx's debt-to-equity ratio decreased from 0.35 to 0.31, a change of −0.04. The latest reported quarter, Q2 2026, shows 0.58.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioLineRx source filings ↗